Tyrosine kinase inhibitors in advanced NSCLC: A case report.


Erlotinib is a molecule that selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity. The authors present a case that exemplifies the use of erlotinib as second line therapy for non-small cell lung cancer (NSCLC). This case is about a 76 years old woman, non-smoker, with advanced lung adenocarcinoma (stage IIIB) previously… (More)
DOI: 10.1016/S0873-2159(15)30318-4